Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 4, 2012

EC Clears First Drug for Short Bowel Syndrome

  • The EC approved Takeda and NPS Pharmaceuticals’ recombinant human glucagon-like peptide 2 (GLP-2) analog Revestive® (teduglutide) as a once-daily treatment for adults with short bowel syndrome (SBS). The drug is the first to be approved for this indication in Europe.

    Regulatory clearance was based on data from the placebo-controlled Phase III Steps study in 43 SBS patients who required parenteral nutrition. Data showed that treatment with teduglutide more than doubled the percentage of patients who achieved a 20% to 100% reduction in parenteral nutrition at week 20 and 24, and reduced the volume of parenteral nutrition required by 4.4 liters per week. 54% of patients receiving teduglutide achieved an at least one-day reduction in parenteral nutrition, versus 23% of placebo-treated patients.

    NPS Pharmaceuticals granted Nycomed (which was acquired by Takeda in September 2011) rights to develop and commercialize teduglutide outside the U.S., Canada, Mexico, and Israel in 2007. NPS retains all rights to the drug in North America, and submitted an NDA to FDA in November 2011, under the trade name Gattex®.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »